Pemigatinib is a type of inhibitor that focuses on FGFR proteins. It’s especially for cholangiocarcinoma patients with FGFR2 fusions. It’s made to mess with the FGFR signaling pathway.
The drug is in tablet form and comes in three strengths: 4.5 mg, 9 mg, or 13.5 mg. The 13.5 mg dose is what they usually recommend. You usually take one 13.5 mg tablet every day for 14 days out of every 21-day period.
The tablets come in packs with 14 in each. Pemigatinib was made to target pathways in cholangiocarcinoma and other tumors. It aims to cut down on signaling disruptions in cancer cell growth.
This helps with targeted medicine treatment plans because each patient’s tumor might show different levels of FGFR activity. Pemigatinib is a good option for treating cancer cells with FGFR2 mutations or gene fusions. It’s a top pick in cancer treatments for cholangiocarcinomas that often have FGFR fusion genes.
Reviews
There are no reviews yet.